A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...

Ten years of substantial work by Université de Montréal immunologist Nathalie Labrecque's team at the Montreal Clinical ...

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier ...

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on ...

Early clinical results suggest the firm's antibodies targeting the Vβ T-cell receptor could induce strong and durable responses in cancer patients.

FibroGen (FGEN) announced the peer-reviewed publication titled “A Phase 1, First-in-Human Study of FOR46, an Immune-Modulating Antibody-Drug ...

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and autoimmune diseases, will present updated clinical and ...

More information: Dave Maurice De Sousa et al, Early Notch signals from fibroblastic reticular cells program effector CD8+ T cell differentiation, Journal of Experimental Medicine (2025).

这项发现为我们提供了一个全新的视角来评估免疫治疗的长期效果。通过检测患者肿瘤组织中前体耗竭性T细胞（Texp）的比例，我们或许能够更准确地预测他们未来复发的风险，从而为制定更个体化的治疗和随访策略提供依据。